1. Home
  2. CRDL vs VFL Comparison

CRDL vs VFL Comparison

Compare CRDL & VFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CRDL
  • VFL
  • Stock Information
  • Founded
  • CRDL 2017
  • VFL 1993
  • Country
  • CRDL Canada
  • VFL United States
  • Employees
  • CRDL N/A
  • VFL N/A
  • Industry
  • CRDL Biotechnology: Biological Products (No Diagnostic Substances)
  • VFL Finance/Investors Services
  • Sector
  • CRDL Health Care
  • VFL Finance
  • Exchange
  • CRDL Nasdaq
  • VFL Nasdaq
  • Market Cap
  • CRDL 105.8M
  • VFL 117.3M
  • IPO Year
  • CRDL N/A
  • VFL N/A
  • Fundamental
  • Price
  • CRDL $1.37
  • VFL $9.67
  • Analyst Decision
  • CRDL Strong Buy
  • VFL
  • Analyst Count
  • CRDL 3
  • VFL 0
  • Target Price
  • CRDL $9.33
  • VFL N/A
  • AVG Volume (30 Days)
  • CRDL 231.5K
  • VFL 38.0K
  • Earning Date
  • CRDL 08-11-2025
  • VFL 01-01-0001
  • Dividend Yield
  • CRDL N/A
  • VFL 4.16%
  • EPS Growth
  • CRDL N/A
  • VFL N/A
  • EPS
  • CRDL N/A
  • VFL N/A
  • Revenue
  • CRDL N/A
  • VFL N/A
  • Revenue This Year
  • CRDL N/A
  • VFL N/A
  • Revenue Next Year
  • CRDL N/A
  • VFL N/A
  • P/E Ratio
  • CRDL N/A
  • VFL N/A
  • Revenue Growth
  • CRDL N/A
  • VFL N/A
  • 52 Week Low
  • CRDL $0.77
  • VFL $7.93
  • 52 Week High
  • CRDL $2.63
  • VFL $10.77
  • Technical
  • Relative Strength Index (RSI)
  • CRDL 62.48
  • VFL 39.35
  • Support Level
  • CRDL $1.22
  • VFL $9.63
  • Resistance Level
  • CRDL $1.50
  • VFL $9.74
  • Average True Range (ATR)
  • CRDL 0.09
  • VFL 0.09
  • MACD
  • CRDL -0.01
  • VFL -0.00
  • Stochastic Oscillator
  • CRDL 89.29
  • VFL 4.76

About CRDL Cardiol Therapeutics Inc.

Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's main product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.

About VFL abrdn National Municipal Income Fund

Delaware Investments Natl Muni Income is a closed-end investment fund. The Fund seeks to provide current income exempt from regular federal income tax consistent with the preservation of capital. The company's product portfolio includes Mutual funds, Exchange-traded funds, Private markets, Delaware Funds by Macquarie Premier Models, Managed accounts, Closed-end funds, and Variable Insurance Products.

Share on Social Networks: